Groundbreaking Obesity Treatment SYNT-101 Shows Early Promise

Researchers have developed an innovative new obesity treatment called SYNT-101, which shows exciting early promise in a human study. The once-daily oral medication is designed to safely and effectively shift nutrient absorption to the lower intestine, mimicking the effects of gastric bypass surgery without the need for surgery.

The study, presented at the European Congress on Obesity (ECO), evaluated SYNT-101 for safety, tolerance, and its effects on key hormones that control hunger and fullness. The early results are encouraging, with participants tolerating the treatment well and showing signs of appetite control and metabolic benefits.

SYNT-101 works by forming a temporary polydopamine coating in the duodenum, shifting nutrient exposure to the lower intestine to naturally promote satiety and support metabolic balance. This “duodenal nutrient exclusion” effect improves satiety and metabolic regulation and has been shown to better preserve lean muscle mass compared to GLP-1 drugs.

In a pilot study of nine healthy participants, SYNT-101 was found to have a strong safety profile and encouraging metabolic signals. The treatment delayed glucose absorption and increased levels of leptin, a hormone that regulates appetite, while decreasing levels of ghrelin, a hormone that causes hunger.

While larger trials are needed to fully assess the drug’s efficacy and safety, the results are promising for people living with obesity who need novel treatment options that are safe, effective, and affordable. Syntis Bio plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) during the second half of 2025.

The development of SYNT-101 offers hope for people struggling with obesity, particularly those who have not responded well to existing treatments or are unable to afford them. As the study progresses, it may provide a convenient, more sustainable oral alternative to systemic therapies like GLP-1 drugs.

Source: https://scitechdaily.com/new-obesity-pill-mimics-gastric-bypass-without-surgery